Why Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational Drug

The company intends to study the oral formulation of Lucid-MS in a mid-stage clinical trial and test its efficacy on humans as a possible treatment for people to regain mobility lost with multiple sclerosis (MS).

Quantum BioPharma (QNTM) on Monday announced that it has signed an agreement with a leading contract development and manufacturing organization to manufacture an oral drug formulation of Lucid-MS.

The agreement was signed through Quantum’s subsidiary, Huge Biopharma Australia Pty. The company intends to study the oral formulation of Lucid-MS in a mid-stage clinical trial and test its efficacy on humans as a possible treatment for people to regain mobility lost with multiple sclerosis (MS). Multiple Sclerosis is a chronic, often disabling disease that affects the brain and spinal cord.

Get updates to this developing story <directly on Stocktwits.<